Actos (Pioglitazone) Cost in New Hampshire: 2026 Prices, Insurance, and Savings

Pioglitazone is the generic name for the brand-name drug Actos (Takeda), an oral thiazolidinedione (TZD) taken once daily and FDA-approved for glucose control in type 2 diabetes. It has been sold as a generic in the United States since patent exclusivity ended in 2012, and generics now account for nearly all pioglitazone prescriptions filled nationally.

This page covers what is well-established about pioglitazone's cost profile, FDA-approved use, and monitoring requirements, and separates that from New Hampshire-specific coverage and pricing details that change often and that we could not verify against a current, state-specific primary source. Where a claim about New Hampshire Medicaid, a named commercial insurer, or a specific dollar price could not be confirmed against a citable source, we say so directly rather than presenting it as fact.

The single most useful fact for a New Hampshire patient: generic pioglitazone is, nationally, one of the least expensive oral diabetes medications on the market, and its FDA-approved indication is limited to type 2 diabetes management; use for nonalcoholic steatohepatitis (NASH) is off-label, supported by clinical trial data rather than an FDA approval. As of May 2026, exact cash prices, New Hampshire Medicaid coverage status, and any specific pharmacy's price should be confirmed directly, because formularies and cash prices change without notice and no New Hampshire-specific pricing source was available to verify the figures in earlier versions of this page.

What generic status actually tells you about price

Because pioglitazone has been off-patent since 2012, multiple generic manufacturers compete to supply it, which is the main driver of its low price relative to newer diabetes drugs. The FDA's approval history for the original Actos application is public record and confirms the drug's regulatory status and labeling (FDA Actos approval history).

That said, a specific "average New Hampshire cash price" figure requires a live pharmacy pricing source (a discount-card platform query or a survey of New Hampshire pharmacies) that was not available for this draft. What can be said reliably is that generic oral TZDs, as a class, are commonly priced in the low tens of dollars per month at major chain pharmacies without insurance, and that this is dramatically lower than list prices for GLP-1 receptor agonists or SGLT2 inhibitors. Brand-name Actos, when a pharmacy dispenses it instead of generic, carries a materially higher list price than the generic; the exact current list price should be confirmed with the manufacturer or a pharmacy, since list prices move over time.

Does New Hampshire Medicaid cover pioglitazone?

We could not confirm current New Hampshire Medicaid preferred drug list (PDL) status for pioglitazone against a citable, dated state source. Medicaid formularies are reviewed on a rolling basis and a drug's tier or prior-authorization status can change between review cycles. A patient or prescriber should check the current New Hampshire Medicaid PDL directly, or call the pharmacy benefits manager, before assuming coverage either way.

What is generally true across state Medicaid programs, and worth planning around, is that metformin is almost universally the required first-line oral agent, and thiazolidinediones like pioglitazone more often require a prior authorization tied to metformin intolerance, contraindication, or a specific off-label use such as biopsy-confirmed NASH. If a prior authorization is denied, the low generic cash price of pioglitazone (commonly in the range of a basic generic copay, subject to verification at a specific pharmacy) means paying cash may be a reasonable fallback for some patients, though that decision belongs to the patient and prescriber, not this page.

Commercial insurance and Medicare Part D

Generic pioglitazone is typically placed on a low copay tier (Tier 1 or Tier 2) by commercial plans, because it is an inexpensive, long-generic drug with no controlled-substance status and no specialty handling requirement. Brand-name Actos, if a plan covers it at all, is more likely to sit on a non-preferred or higher tier. Exact tier placement and copay amounts differ by specific plan and should be confirmed on the member's own formulary document rather than assumed from a general statement.

Medicare Part D plans have covered generic pioglitazone broadly for years, consistent with its status as a low-cost generic. Under the Inflation Reduction Act's Part D redesign, Medicare beneficiaries now have an annual out-of-pocket cap across all covered Part D drugs (CMS: Inflation Reduction Act and Medicare). For a drug as inexpensive as generic pioglitazone, that cap is unlikely to be reached from pioglitazone spending alone, though it matters more for patients also taking higher-cost medications.

Compounded pioglitazone

Federal law allows 503A compounding pharmacies to prepare patient-specific pioglitazone formulations, for example a non-standard dose or a liquid formulation for a patient who cannot swallow tablets, when a prescriber determines the commercial product is not appropriate for that individual (FDA: compounding laws and policies). This is a general federal rule, not a New Hampshire-specific one; we did not find a New Hampshire Board of Pharmacy document confirming any additional state-level restriction, so patients considering a compounded product should confirm the compounding pharmacy's current New Hampshire license status directly with the pharmacy or the Board of Pharmacy rather than relying on a general statement here. 503B outsourcing facilities that ship compounded drugs into a state must separately register with the FDA and follow current good manufacturing practice requirements; that federal status can be checked on the FDA's 503B facility list.

Compounding is appropriate for a documented clinical need, not simply as a way to obtain a lower price than a commercially available generic tablet that already meets the patient's needs.

Telehealth prescribing

Pioglitazone is not a controlled substance, so a telehealth visit to start or continue it does not trigger the DEA's controlled-substance telehealth restrictions that apply to some other drug classes. Beyond that general point, we did not have a verified, dated New Hampshire-specific telehealth statute citation to support more detailed claims about parity requirements or specific reimbursement rules, so a patient relying on telehealth for pioglitazone should confirm coverage and any visit requirements with their own insurer and prescriber.

Before starting pioglitazone, baseline liver function testing (ALT) is part of the FDA label's recommendation, and this can reasonably be completed at any local lab and shared with a telehealth prescriber.

Off-label use for NASH: what the evidence actually shows

Pioglitazone's FDA-approved indication is type 2 diabetes. Its use in nonalcoholic steatohepatitis (NASH, now often described under the broader term MASLD/MASH) is off-label. A randomized trial (commonly referred to as the PIVENS trial) compared pioglitazone, vitamin E, and placebo in patients with non-diabetic NASH and reported a meaningfully higher rate of histologic improvement with pioglitazone than placebo over roughly two years of treatment. We are not citing a specific PMID or number here because the exact figures require verification against the primary publication rather than being repeated from an unverified secondary citation; a clinician recommending pioglitazone for NASH should reference the current AASLD practice guidance and the primary trial literature directly.

Separately, cardiovascular outcome trials in patients with type 2 diabetes and in insulin-resistant patients after stroke or TIA have examined pioglitazone's effect on major cardiovascular events. These are real, well-known trials in the pioglitazone literature (commonly referenced under names like PROactive and IRIS), but this page does not restate specific relative-risk percentages, because the underlying citation chain in the source material for this page could not be confirmed against the correct primary paper. A clinician or patient wanting exact effect sizes should pull the original trial publications rather than rely on a secondary repetition of a number.

Safety signals that affect the true cost of treatment

The FDA label for pioglitazone carries a boxed warning about the risk of congestive heart failure exacerbation from fluid retention, and pioglitazone is generally avoided or used with caution in patients with NYHA Class III or IV heart failure (FDA label information). Weight gain and fluid retention are recognized class effects. An earlier bladder cancer signal associated with pioglitazone use prompted a large, FDA-mandated long-term cohort study; the FDA subsequently updated labeling based on that follow-up data, though cautionary language remains. Anyone relying on the exact result of that cohort study for a clinical decision should pull the primary publication rather than a secondary restatement.

Routine monitoring, most importantly baseline and periodic liver enzyme testing, adds a real but modest cost to pioglitazone therapy. A basic metabolic or liver panel is billed through standard clinical laboratory fee schedules, which vary by payer and lab; an uninsured patient's actual out-of-pocket lab cost should be confirmed with the specific lab used.

What is established, what is plausible, and what is not established

Established: Pioglitazone is FDA-approved only for type 2 diabetes, has been generic since 2012, carries a boxed warning for heart failure exacerbation risk, and requires baseline and periodic liver enzyme monitoring per the FDA label. Federal law permits 503A compounding of patient-specific formulations when clinically justified.

Plausible but requiring primary-source verification for exact numbers: The magnitude of cardiovascular risk reduction reported in pioglitazone outcome trials, the exact histologic response rate reported in NASH trials, and the precise long-term bladder cancer risk estimate from cohort follow-up data. These effects are part of the real pioglitazone evidence base, but the specific percentages should be pulled from the primary trial publications rather than taken from a secondary summary.

Not established from anything verifiable for this page: A specific current New Hampshire average cash price for generic or brand pioglitazone, New Hampshire Medicaid's current prior-authorization approval rate for thiazolidinediones, and any New Hampshire-specific telehealth statute detail beyond the general federal point that pioglitazone is not a controlled substance. These require direct verification with a New Hampshire pharmacy, the state Medicaid program, or a New Hampshire-licensed telehealth prescriber before a reader acts on them.

Verification checklist: stable facts versus facts you must confirm today

Use this to separate what you can rely on from what changes and needs a fresh check before you make a coverage or purchasing decision.

Stable, federally anchored facts (unlikely to change month to month):

• Pioglitazone's FDA-approved indication is type 2 diabetes; NASH use is off-label.
• The FDA label carries a boxed warning for heart failure exacerbation risk.
• Baseline and periodic liver enzyme (ALT) monitoring is part of the FDA labeling recommendation.
• Pioglitazone is not a federally controlled substance.
• 503A pharmacies may compound patient-specific pioglitazone formulations under federal law when clinically justified; 503B outsourcing facilities must be FDA-registered.
• Generic pioglitazone has been available since patent expiration in 2012.

Date-sensitive facts you should confirm before relying on them (check each with its own source, not this page):

• Current New Hampshire Medicaid PDL status and any prior-authorization criteria for pioglitazone: confirm with the NH Medicaid pharmacy benefits manager directly.
• Your specific commercial or Part D plan's tier placement and copay for generic versus brand pioglitazone: confirm on your plan's current formulary document.
• Cash price at a specific New Hampshire pharmacy, with or without a discount card: confirm at the pharmacy counter or through the discount platform at the time of fill.
• Any manufacturer savings card terms and eligibility restrictions: confirm directly on the manufacturer's current program page.
• Whether a specific 503A or 503B compounding pharmacy holds an active New Hampshire license and relevant accreditation: confirm with the pharmacy or the New Hampshire Board of Pharmacy.
• Whether a specific telehealth platform or prescriber is licensed in New Hampshire and whether your insurer reimburses that visit type: confirm with the prescriber and your insurer.

If a claim in an older version of this page, or from another source, gives you a specific dollar figure or approval percentage for New Hampshire, treat it as unverified until you can check it against one of the sources above.

Questions patients actually ask

Is pioglitazone the same as Actos? Yes. Pioglitazone is the generic name; Actos is Takeda's original brand name for the same active ingredient. The generic has been available since 2012 and is chemically identical in active ingredient to brand-name Actos, though inactive ingredients can differ between manufacturers.

Can pioglitazone be prescribed for NASH instead of diabetes? It can be prescribed off-label for NASH based on trial evidence, but this is not an FDA-approved indication and should be a decision made with a clinician familiar with the evidence and with your liver and cardiac history, not a self-directed request.

Does having heart failure rule out pioglitazone? The FDA label specifically warns against use in more advanced heart failure (NYHA Class III or IV) because of fluid retention risk. Anyone with a heart failure history should discuss this directly with their prescriber before starting or continuing pioglitazone.

Do I need blood tests before starting pioglitazone? Yes. Baseline liver enzyme testing is part of the FDA labeling recommendation, with periodic rechecks during treatment.

Should I assume New Hampshire Medicaid will or will not cover pioglitazone? Neither assumption is safe without a current check. Formulary and prior-authorization rules change, and the only reliable answer comes from the state Medicaid pharmacy benefits manager at the time you need the prescription filled.

References

1. U.S. Food and Drug Administration. Actos (pioglitazone) prescribing information and approval history. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021073
2. U.S. Food and Drug Administration. Compounding laws and policies. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
3. Centers for Medicare & Medicaid Services. Inflation Reduction Act and Medicare Part D redesign. https://www.cms.gov/inflation-reduction-act-and-medicare
4. U.S. Food and Drug Administration. FDA approves first treatment for patients with liver scarring due to fatty liver disease. March 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

Note for editorial review: the source draft included attributed quotations from physicians and PubMed citations for pioglitazone trial outcomes (PROactive, IRIS, PIVENS, bladder cancer cohort analyses, and AACE guidelines) that require verification against original sources. These quotations and citations have been provisionally removed pending confirmation. Before publication, please consult the original PIVENS, PROactive, IRIS, and bladder cancer cohort studies to verify reported pioglitazone efficacy data and restore properly matched citations, and verify any New Hampshire-specific regulatory claims regarding Medicaid, insurance coverage, or telehealth policy against current state documentation.